The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance by Alnabulsi, Abdo et al.
1 
 
The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in 
colorectal cancer and its prognostic significance 
 
Abdo Alnabulsi1,2, Rebecca Swan1, Beatriz Cash2, Ayham Alnabulsi2, Graeme I Murray1 
 
1Pathology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, 
Aberdeen, AB25, 2ZD, UK.  2Vertebrate Antibodies, Zoology Building, Tillydrone Avenue, 
Aberdeen, AB24 2TZ, UK. 
 
Address correspondence to: Professor Graeme I Murray 
Email g.i.murray@abdn.ac.uk 
Phone: +44(0)1224 553794 
Fax: +44(0)1224 663002 
 
 
Running title: omega hydroxylases and colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
Abstract 
Background: Colorectal cancer is a common malignancy and one of the leading causes of 
cancer related deaths.  The metabolism of omega fatty acids has been implicated in tumour 
growth and metastasis. 
Methods: This study has characterised the expression of omega fatty acid metabolising 
enzymes CYP4A11, CYP4F11, CYP4V2 and CYP4Z1 using monoclonal antibodies we have 
developed.  Immunohistochemistry was performed on a tissue microarray containing 650 
primary colorectal cancers, 285 lymph node metastasis and 50 normal colonic mucosa.  
Results: The differential expression of CYP4A11 and CYP4F11 showed a strong association 
with survival in both the whole patient cohort (HR=1.203, 95% CI=1.092-1.324, χ2=14.968, 
p=0.001) and in mismatch repair proficient tumours (HR=1.276, 95% CI=1.095-1.488, 
χ2=9.988, p=0.007).  Multivariate analysis revealed that the differential expression of 
CYP4A11 and CYP4F11 was independently prognostic in both the whole patient cohort 
(p = 0.019) and in mismatch repair proficient tumours (p=0.046). 
Conclusions: A significant and independent association has been identified between overall 
survival and the differential expression of CYP4A11 and CYP4F11 in the whole patient 
cohort and in mismatch repair proficient tumours. 
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Introduction 
Colorectal cancer is one of the major contributors to cancer related mortality in the 
developed world (Siegel et al, 2014, Siegel et al, 2016).  The introduction of screening 
programmes and the development of new drugs have improved the survival rate of colorectal 
cancer patients, however the average five-year survival rate remains poor at 55% (Brenner et 
al, 2014).  The characterisation of novel biomarker targets can further improve the survival 
rate since it provides a better understanding of the complex molecular events underpinning 
tumour development, and if clinically validated these biomarkers have potential roles in 
screening, diagnosis, prognosis and monitoring disease progression (Alnabulsi and Murray, 
2016, Coghlin and Murray, 2015). 
The CYP4 cytochrome P450 family of enzymes metabolises omega-3 and omega-6 
fatty acids to biologically active eicosanoids that are implicated in tumour initiation, 
development and progression (Johnson et al, 2015, Yu et al, 2011).  Arachidonic acid, an 
omega-6 fatty acid, is converted by CYP4A11 to 20-hydroxyicosatetraenoic acid (20-HETE) 
which is considered a key modulator in tumours progression, angiogenesis and metastasis 
(Guo et al, 2007, Ljubimov and Grant, 2005).  CYP4F11 is not an efficient metaboliser of 
arachidonic acid compared to CYP4A11, however it is the predominant CYP4 enzyme 
involved in the metabolism of omega 3-fatty acids (Dhar et al, 2008).  The substrate 
specificity is not yet fully characterised for CYP4V2 and CYP4Z1 (Guengerich and Cheng, 
2011).  Despite the recognition of the involvement of omega fatty acids in tumourigenesis, 
the role of the cytochrome P450 enzymes involved in this pathway has received very limited 
attention in cancer biology (Panigrahy et al, 2010).   
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Using monoclonal antibodies we have developed to the cytochrome P450 enzymes 
CYP4A11, CYP4F11, CYP4V2 and CYP4Z1, this study has profiled the expression of these 
enzymes by immunohistochemistry on a tissue microarray containing a large and well-
characterised cohort of colorectal cancers.  The expression profile of each enzyme was 
established by light microscopy using a semi-quantitative scoring system.  The prognostic 
significance of each enzyme was determined by assessing the relationship between their 
expression in tumours and overall survival.   
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Materials and methods 
Monoclonal antibody development 
Monoclonal antibodies to CYP4A11, CYP4V2 and CYP4Z1 were developed using 
short synthetic peptides (Murray et al, 1998).  Multiple sequence alignments of the amino 
acid sequences were performed on these enzymes and other CYP4 family members to 
identify regions with the highest amino acid diversity.  To avoid poorly antigenic sequences 
of amino acids (e.g. transmembrane region), a range of bioinformatics tools were used to 
predict and model hydrophilic, accessible and antigenic polypeptide sequences as well as the 
secondary and tertiary structures of each enzyme (Supplementary Materials and Methods S1).  
The amino acid sequences of peptides used to generate the antibodies and their 
location on each enzyme are specified in Supplementary Table S1.  All peptides (Almac 
Sciences Ltd, Edinburgh, UK) were conjugated to ovalbumin for immunisations and to 
bovine serum albumin for the enzyme-linked immunosorbent assay (ELISA) screenings 
(Duncan et al, 1992).  The immunisation via the subcutaneous route, the production of 
hybridomas and the ELISA screenings were carried out as previously described (Brown et al, 
2014, Murray et al, 1996, Murray et al, 1998).  The development of the monoclonal antibody 
to CYP4F11 has been described previously (Kumarakulasingham et al, 2005). 
 
Immunoblotting 
The specificity of the monoclonal antibodies was established by immunoblotting 
using whole cell lysate (human embryonic kidney cells-HEK 293, Novus Biologicals, 
Cambridge, UK) overexpressing the relevant CYP as a positive control and lysates from cells 
containing empty vector as a negative control.  Microsomal fractions prepared from human 
liver tissues (BD Gentest Human Liver Microsomes (HLM) Pooled Male Donors 20 mg/mL 
cat no. 452172, BD Biosciences, Bedford, USA) were also used to carry out immunoblotting 
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validation for each antibody.  The immunoblotting was carried out as described, except that 
the polyvinylidene difluoride membrane was incubated overnight at 4°C with undiluted 
monoclonal antibody (neat hybridoma tissue culture supernatant), and the secondary 
antibody, horseradish-peroxidase-conjugated anti-mouse IgG (Sigma-Aldrich, Dorset, UK), 
was diluted 1/3000 in phosphate buffered saline-Tween-20 (Swan et al, 2016).  When using 
liver microsomes, 30 μg of samples were loaded per lane compared to 5 μg when using 
overexpression lysate.   
 
Patient cohort and colorectal cancer tissue microarray 
The patient cohort was retrospectively acquired from the Grampian Biorepository 
(www.biorepository.nhsgrampian.org).  The cohort is composed of tissue samples from 650 
patients who had undergone surgery for primary colorectal cancers between 1994 and 2009, 
at Aberdeen Royal Infirmary (Aberdeen, UK) which is the principal teaching hospital of NHS 
Grampian.  Patients who had received neoadjuvant chemotherapy and/or radiotherapy were 
excluded.   
Survival time was defined to be the period in whole months from the date of surgery 
to the date of death from any cause (i.e. all-cause mortality).  Survival data on a 6-monthly 
basis was updated from the NHS Grampian electronic patient management system and no 
patients were lost to follow-up.  At the time (March 2012) of the censoring of patient 
outcome data there had been 309 (47.5%) deaths and patients who were still alive were 
censored.  The median survival was 103 months (95% CI=86–120 months), the mean 
survival was 115 months (95% CI=108–123 months) and the median follow-up time, 
calculated by the “reverse Kaplan-Meier” method, was 88 months (95% CI=79–97 months).  
The clinico-pathological characteristics of the patients and their association with survival are 
described in Table 1. 
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Histopathology reporting was in accordance with The Royal College of Pathologists 
UK guidelines for the histopathological reporting of resection specimens of colorectal cancer 
which includes guidance from version 5 of the tumour, node, metastasis (TNM) staging 
system (Williams et al, 2007).   
 Blocks of formalin fixed, paraffin embedded tissue specimens were used to construct 
the tissue microarray as previously described (Brown et al, 2014, O'Dwyer et al, 2011, Swan 
et al, 2016).  The histopathological processing of tissue specimens and the construction of the 
tissue microarray are described in Supplementary Materials and Methods S1  
 
Immunohistochemistry 
 A Dako autostainer (Dako, UK) was used to perform the immunohistochemistry for 
each antibody using the Dako EnVision™ system (Dako, Ely, UK) (Brown et al, 2014, 
Kumarakulasingham et al, 2005).  Antigen retrieval (microwaving in 10mM citrate buffer pH 
6.0 for 20 minutes) was performed for all antibodies except CYP4A11.  The 
immunohistochemistry procedure and the antigen retrieval are described in Supplementary 
Materials and Methods S1.  A semi-quantitative scoring system was used to evaluate the 
intensity of immunostaining of each antibody (Brown et al, 2016, Kumarakulasingham et al, 
2005, O'Dwyer et al, 2011, Swan et al, 2016).  The scoring was conducted independently by 
two observers (RS and GIM) who were unaware of the clinical data and outcome.  The 
assessment of cores was performed using light microscopy (Olympus BX 51, Olympus, 
Southend-on- Sea, Essex, UK).  Simultaneous re-evaluation of the cores by both investigators 
was used to resolve any discrepancies in the scores (< 5% of cases).  
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Assessment of mismatch repair protein (MMR) status 
The status of MMR in the patient cohort was classified as either defective or 
proficient based on the immunohistochemical assessment of MLH1 and MSH2 proteins 
(Brown et al, 2014). 
 
Data analysis and statistics 
The data was entered into an Excel 2013 spreadsheet before being analysed using 
IBM SPSS version 24 for Windows 7™ (IBM, Portsmouth, UK).  The following statistical 
tests were used; Mann-Whitney U test, Wilcoxon signed rank test, chi-squared test, Kaplan-
Meier survival analysis, log-rank test and Cox multivariate analysis (variables entered as 
categorical variables) including the calculation of hazard ratios and 95% CIs.  A probability 
value of p≤0.05 was regarded as statistically significant.  The survival analysis of the 
different patients groups was conducted using the log rank test.  The scores for each protein 
were dichotomised using the following cut-off points; negative staining versus positive 
staining, negative and weak staining versus moderate and strong staining and strong staining 
versus negative/weak/ moderate staining.  Further details of data analysis and statistics are 
provided in Supplementary Materials and Methods S1. 
 
Ethics 
The use of colorectal tissue samples in this study was approved by the Grampian 
Biorepository scientific access group committee (Tissue request No. 0002).  No written 
consent was required from patients for the use of formalin fixed wax embedded tissue 
samples in the colorectal cancer tissue microarray. 
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Results 
Monoclonal antibodies  
During the hybridoma production, sequential ELISA screenings (immunogenic 
peptide specific to each enzyme) were used to determine the specificity of the monoclonal 
antibodies towards CYP4A11, CYP4V2 and CYP4Z1 (Duncan et al, 1992).  Furthermore, 
immunoblotting showed a band migrating at the expected molecular weight for each antibody 
while no band was detected in the negative controls (Supplementary Figure S1).  The 
specificity of the antibody to CYP4F11 was confirmed previously (Kumarakulasingham et al, 
2005). 
 
Immunohistochemistry 
CYP4A11, CYP4F11 and CYP4V2 antibodies showed immunoreactivity in normal 
colonic epithelium, primary colorectal tumours and lymph node metastasis, while CYP4Z1 
showed immunoreactivity only in a very small proportion of primary tumours.  The 
immunostaining was exclusively localised to the cytoplasm of the cells (Supplementary 
Figure S2).  Intra-tumour heterogeneity was not observed in either primary or metastatic 
colorectal tumours. 
There was a significant increase in the intensity of immunostaining in primary 
tumours compared to normal colonic mucosa for CYP4A11 (p<0.001), CYP4F11 (p<0.001) 
and CYP4V2 (p<0.001) (Table 2; Supplementary Figure S3).  In contrast, a significant 
decrease in the expression of CYP4A11 (p=0.007), CYP4F11 (p<0.001) and CYP4V2 
(p<0.001) was observed in lymph node metastasis compared with all primary tumours.  There 
was also a significant decrease in the expression of CYP4A11 (p=0.002), CYP4F11 
(p<0.001) and CYP4V2 (p<0.001) in lymph node metastasis compared to their corresponding 
primary Dukes C tumours. 
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Relationship with pathological parameters 
The relationships between the main pathological parameters and the expression of 
CYP4A11, CYP4F11, CYP4V2 and CYP4Z1 are summarised in Supplementary Tables S2A, 
B and C.  Both CYP4A11 (χ2=13.148, p=0.041) and CYP4V2 (χ2=24.474, p<0.001) showed 
significant associations with Dukes stage, but only CYP4V2 displayed a significant 
relationship with tumour stage (χ2=17.837, p=0.037).  The expression of CYP4A11 was 
significantly associated with tumour site (χ2=15.703, p=0.015).  CYP4F11 also showed 
significant associations with tumour site (χ2=20.947, p=0.002), tumour differentiation 
(χ2=8.5552, p=0.036) and MMR status (χ2=13.441, p=0.004).   
 
Survival analysis 
Whole patient cohort 
Different cut-off points of the immunostaining scores were used to investigate the 
association between the expression of CYP4A11, CYP4F11 and CYP4V2 and overall 
survival (Supplementary Table S3).  The expression of CYP4A11 showed a consistent and 
significant association with overall survival (Figure 1).  Overall, increasing intensity of 
CYP4A11 immunostaining was significantly associated with poorer outcome (HR=1.135, 
95% CI=1.032-1.249, χ2 =9.080, p=0.028).  When each level of the intensity groups of 
CYP4A11 expression was considered independently using one reference group (negative 
expression), strong CYP4A11 immunostaining was significantly associated with poorer 
outcome (HR=1.541, 95% CI=1.144-2.077, χ2 =8.006, p=0.005) (Supplementary Table S4).  
 The median survival was 137 months (95% CI undefined) and the mean was 132 
months (95% CI = 117-147 months) for CYP4A11 negative tumours (n = 175), whereas the 
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median survival was 75 months (95% CI=58-91 months) and the mean was 96 months (95% 
CI=84-109 months) for CYP4A11 strong expression tumours (n = 197).  
Immunoreactivity for CYP4A11 was significantly associated with poorer prognosis 
(HR=1.346, 95% CI=1.032-1.756, χ2 =4.881, p=0.027) when compared with CYP4A11 
negative tumours.  For CYP4A11 positive tumours (n=450) the median survival was 88 
months (95% CI = 71-104 months) and the mean was 105 months (95% CI = 96-114 months), 
compared to a median of 137 (95% CI undefined) and a mean of 132 months (95% CI = 117-
147 months) for CYP4A11 negative tumours (n=175).  Comparing strong CYP4A11 
expressing tumours with negative/weak/moderate expressing tumours also showed a 
significant association with survival (HR = 1.379, 95% CI = 1.089–1.746, χ2 = 7.234, p = 0.007).  
The median survival was 113 months (95% CI = 89-136 months) and the mean was 124 
months (95% CI = 114-134 months) for negative/weak/moderate CYP4A11 immunostaining 
tumours (n = 428), whereas the median survival was 75 months (95% CI = 58-91 months) and 
the mean was 96 months (95% CI = 84-109 months) for strong CYP4A11 immunostaining 
tumours (n = 197).   
Exploratory analysis of CYP4 enzyme expression showed there was a significant 
association between the differential (combined) expression of CYP4A11 and CYP4F11 and 
survival (Supplementary table S5).  Therefore, a new variable, based on the differential 
expression of CYP4A11 and CYP4F11, was created to stratify tumours into three groups; 
CYP4A11 greater than CYP4F11 (CYP4A11>CYP4F11), CYP4A11 equal to CYP4F11 
(CYP4A11=CYP4F11) and CYP4A11 less than CYP4F11 (CYP4A11<CYP4F11).  Overall 
survival was significantly associated with the expression profiles of CYP4A11>CYP4F11, 
CYP4A11=CYP4F11 and CYP4A11<CYP4F11 groups (HR=1.311, 95% CI=1.140-1.506, 
χ2=14.968, p=0.001) (Figure 2).  When each level of the differential expression groups was 
considered independently using pairwise comparisons and one reference group 
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(CYP4A11<CYP4F11), both CYP4A11>CYP4F11 (HR=1.733, 95% CI=1.306-2.300, 
χ2=14.405, p=<0.001) and CYP4A11=CYP4F11 (HR=1.432, 95% CI=1.064-1.928, χ2=5.425, 
p=0.020) were significantly associated with poorer outcome (Supplementary Table S6).  The 
mean survival was 137 months (95% CI= 124-151 months) (median survival undefined) for 
the CYP4A11<CYP4F11 group (n=214), the median survival was 95 months (95% CI=72-
117 months) and the mean was 102 months (95% CI=90-114 months) for the 
CYP4A11=CYP4F11 group (n=185), while the median survival was 75 months (95% CI=60-
89 months) and the mean survival was 94 months (95% CI=81-106 months) for 
CYP4A11>CYP4F11 group (n=217). 
The associations between the expression of CYP4A11, CYP4F11, CYP4V2 and 
CYP4Z1 and overall survival in relation to different tumour sites, Dukes stage and extramural 
venous invasion (EMVI) are shown in Supplementary Tables S7, S8, S9 and S10. 
 
MMR proficient cohort 
There was a significant association between the expression of CYP4A11 and overall 
survival in MMR proficient tumours (HR=1.156, 95% CI=1.040-1.286, χ2=11.221, p=0.011) 
(Figure 3; Supplementary Table S11).  When each level of the intensity groups of CYP4A11 
expression was considered separately using pairwise comparisons and one reference group 
(negative expression), strong CYP4A11 immunoreactivity was significantly associated with 
poorer prognosis (HR=1.644, 95% CI=1.183-2.284, χ2=8.626, p=0.003) (Supplementary 
Table S4).  When comparing strong CYP4A11 expressing tumours with 
negative/weak/moderate expressing tumours the strong expression of CYP4A11 showed a 
significant association with worse survival (HR=1.491, 95% CI=1.152-1.929, χ2=9.404, 
p=0.002).  The positive expression of CYP4A11 was also significantly associated with poorer 
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outcome when positive CYP4A11 expressing tumours were compared with negative 
CYP4A11 expressing tumours (HR=1.375, 95% CI=1.022-1.851, χ2=4.485, p=0.034).   
There was also a significant association between the differential expression of 
CYP4A11 and CYP4F11 and survival in MMR proficient tumours (HR=1.276, 95% 
CI=1.05-1.488, χ2=9.988, p=0.007) (Figure 2).  When each level of the intensity groups was 
considered independently using pairwise comparisons and one reference group 
(CYP4A11<CYP4F11), CYP4A11>CYP4F11 expressing tumours were significantly 
associated with poorer outcome (HR=1.629, 95% CI=1.199-2.214, χ2=9.261, p=0.002) 
(Supplementary Table S6).  The median survival was 75 months (95% CI=85-121 months) 
and the mean was 97 months (95% CI=83-111 months) for CYP4A11>CYP4F11 expressing 
tumours (n=181).  While, the mean survival was 137 months (95% CI=123-151 months) 
(median survival undefined) for CYP4A11<CYP4F11 expressing tumours (n=186).   
 
MMR deficient cohort 
 The lack of expression of CYP4F11 was significantly associated with worse overall 
survival compared with CYP4F11 positive tumours (HR=0.479, 95% CI=0.241-0.952, 
χ2=4.682, p=0.03) (Supplementary Table S11; Supplementary Figure S4).  The median 
survival was 28 (95% CI=21-34 months) and the mean was 49 months (95% CI =28 –70 
months) for CYP4F11 negative tumours (n=16) compared with a median of 114 (95% CI=78-
149 months) and a mean of 104 months (95% CI= 84-123 months) for CYP4F11 positive 
tumours (n=77).  
Overall, the association between survival and the differential expression of CYP4A11 
and CYP4F11 just failed to reach the threshold for statistical significance in MMR deficient 
cohort (HR=1.433, 95% CI=0.993-2.067, χ2=5.676, p=0.059) (Figure 2).  When each level of 
the intensity groups was considered independently using pairwise comparisons and one 
14 
 
reference group (CYP4A11<CYP4F11), both CYP4A11>CYP4F11 expressing tumours 
(HR=1.733, 95% CI=1.306-2.300, χ2=14.405, p=<0.001) and CYP4A11=CYP4F11 
expressing tumours (HR=1.432, 95% CI=1.064-1.928, χ2=5.425, p=0.020) were significantly 
associated with poorer outcome (Supplementary Table S6).   
 
Multivariate analysis 
To evaluate the prognostic value of the differential expression of CYP4A11 and 
CYP4F11 (as a single variable) in relation to established prognostic parameters multivariate 
analysis was performed using “Forward Stepwise: Conditional LR” Cox regression method.  
The model showed there was a significant and independent prognostic value of using the 
differential expression of CYP4A11 and CYP4F11 in the whole patient cohort (p=0.019) and 
in MMR proficient tumours (p=0.046) (Table 3; Supplementary Tables S12 and S13).  The 
differential expression was also a significant independent prognostic indicator in a 
multivariate analysis using only parameters that would be available at the time of biopsy in 
both the whole patient cohort (p=0.001) and in MMR proficient tumours (p=0.006) 
(Supplementary Table S14).   
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Discussion 
The rise in incidence and the poor survival rate makes colorectal cancer a major 
health burden in the developed world (Brenner et al, 2014, Siegel et al, 2014, Siegel et al, 
2016).  There is still urgent need to identify and validate biomarkers of colorectal cancer that 
can play a role in clinical practice (Alnabulsi and Murray, 2016). 
In this study, we have produced monoclonal antibodies to P450 enzymes CYP4A11, 
CYP4V2 and CYP4Z1 using short synthetic peptides that are specific to the targets of 
interest.  The antibody for CYP4F11 was generated in a previous study (Kumarakulasingham 
et al, 2005).  The antibodies were used to profile the expression of each enzyme by 
immunohistochemistry which was performed on a well-characterised colorectal cancer tissue 
microarray. 
The cytochrome P450 superfamily is classified into families, subfamilies and 
individual forms according to sequence homology and substrate specificity (Almira Correia 
et al, 2011, Fleming, 2011, Spector, 2009).  Members of CYP1, CYP2 and CYP3 families are 
the major xenobiotic metabolising enzymes whose roles in cancer have been extensively 
studied (Murray et al, 1991, Murray et al, 1993, Murray et al, 1999, Murray et al, 2001, 
Murray et al, 2010, Rodriguez-Antona et al, 2010, Stenstedt et al, 2012, Xu et al, 2012).  The 
CYP4 and higher numbered families are involved in the metabolism of a diverse range of 
endogenous compounds including eicosanoids, fatty acids, steroids and vitamins (Arnold et 
al, 2010, Fleming, 2011, Guengerich and Cheng, 2011, Niwa et al, 2011, Panigrahy et al, 
2010, Spector, 2009).  The role of CYP4 family and higher numbered families is not well 
studied in tumour biology with the exception of those CYPs involved in sex hormone 
metabolism in relation to breast and prostate cancer (Brueggemeier et al, 2005, Leroux, 2005, 
Stein et al, 2012).  Therefore, this study aimed to examine the role of the main CYP4 family 
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enzymes in colorectal cancer by characterising the expression of these enzymes using a large 
and well-characterised patient cohort. 
This study revealed there was a significant increase in the expression of CYP4A11 in 
primary colorectal tumours compared to normal colonic mucosa and the increased expression 
was significantly associated with poorer prognosis.  Consistent with our finding, an 
upregulation of CYP4A11 was demonstrated by a cDNA microarray-bioinformatics analysis 
of 10 colorectal tumours and their corresponding normal tissues (Yeh et al, 2006).  
Furthermore, the overexpression of CYP4A11 has been linked to rise in 20-HETE levels and 
upregulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinases-9 
(MMP-9) in non-small cell lung cancer (Yu et al, 2011).  Both VEGF and MMP-9 are strong 
promoters of tumour invasion and metastasis (Brown and Murray, 2015, Goel and Mercurio, 
2013, Yu et al, 2011).  Previous research also showed that using selective inhibitors to 
downregulate the expression of CYP4A11 in cell lines and animal models resulted in a 
decrease in tumour growth, angiogenesis and metastasis of non-small cell lung cancer, renal 
adenocarcinoma and glioma (Alexanian et al, 2009, Guo et al, 2008, Yu et al, 2011).  Our 
data has shown CYP4A11 is overexpressed in colorectal cancer, therefore CYP4A11 may be 
a relevant therapeutic target in this type of cancer. 
Comparing primary colorectal tumours to normal colonic mucosa also showed there 
was a significant increase in the expression of CYP4F11 which is a novel finding. In recent 
research, CYP4F11 expressed in cell lines (non-small cell lung cancer) converted oxalamides 
and benzothiazoles into stearoyl CoA desaturase (SCD) inhibitors (Theodoropoulos et al, 
2016). SCD is emerging as a therapeutic target in cancer and therefore, colorectal tumours 
with high CYP4F11 expression may be a valid target for SCD targeted therapy.  
The differential expression of CYP4A11 and CYP4F11 emerged as the best 
prognostic marker in this study.  The distinct prognostic impact of the differential expression 
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of CYP4A11 and CYP4F11 may be explained by differences in the enzymes substrates 
(Supplementary Figure S5).  CYP4A11 converts arachidonic acid to metabolites that promote 
tumour growth and metastasis, while CYP4F11 metabolises omega 3-fatty acids to 
eicosanoids that inhibit tumour development and progression (Barone et al, 2014, Dhar et al, 
2008, Gelsomino et al, 2013, Kalsotra and Strobel, 2006, Larsson et al, 2004).  The 
differential expression of CYP4A11 and CYP4F11 was independently prognostic in 
multivariate analysis using the main prognostic parameters and also when only using 
information available at the time of biopsy diagnosis of colorectal cancer.  Therefore, this 
biomarker combination could be a useful risk stratification tool especially if only tumour 
biopsies are available at the time of initial treatment decisions, which is a likely scenario 
considering colorectal cancer, especially rectal cancer, is moving towards neoadjuvant 
therapy followed by either observational follow-up or salvage surgery (Garcia-Aguilar et al, 
2015). 
The expression of each enzyme based on MMR status was also evaluated in this study 
since this represents a major pathway in colorectal cancer (Boland and Goel, 2010, 
Geiersbach and Samowitz, 2011, Kim and Kim, 2014).  Tumours lacking MMR proteins are 
already considered a distinct subgroup when dealing with prognosis and treatment of 
colorectal cancer (Hewish et al, 2010).  MMR proficient tumours represent the majority of 
colorectal cancer cases with a significantly worse prognosis than MMR deficient tumours.  
Furthermore, novel promising treatments such as those targeting immune checkpoints have 
shown that MMR proficient tumours are less responsive compared to MMR deficient 
tumours (Le et al, 2015).  Therefore, it is of particular interest to identify biomarkers for 
MMR proficient tumours.  In this study, the differential expression of CYP4A11 and 
CYP4F11 was significantly associated with prognosis in MMR proficient tumours, and more 
importantly both enzymes are actionable targets. 
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 This study also found the expression of CYP4A11, CYP4F11 and CYP4V2 were 
significantly reduced in lymph node metastasis compared with their corresponding primary 
tumours.  This provides further evidence to the concept that the phenotype of cancer cells is 
defined by their exposure to/ and interaction with different microenvironment factors during 
their migration and within the metastatic site (Brown and Murray, 2015, Klein et al, 2012, 
Maman and Witz, 2013, Witz, 2008).  The interrelationship between cancer cells and non-
cancer cells within the microenvironment is increasingly acknowledged as a major factor in 
determining and understanding metastasis (Coghlin and Murray, 2010, Coghlin and Murray, 
2014, McKay et al, 2000).  The variation in the phenotypic expression between primary and 
metastatic tumours raises further doubts over the effectiveness of existing metastatic 
treatment models that is based on phenotypic assessment of primary tumour specimens.   
In summary, CYP4A11, CYP4F11 and CYP4V2 are overexpressed in colorectal 
cancer, the increased expression of CYP4A11 is associated with poorer prognosis in both the 
total patient cohort and in MMR proficient tumours, while the expression of CYP4F11 is 
associated with better outcome in MMR deficient tumours.  The differential expression of 
CYP4A11 and CYP4F11, which was independently prognostic in both the whole patient 
cohort and in MMR proficient tumours, could provide the basis for a risk stratification tool in 
colorectal cancer.  Furthermore, both enzymes are actionable drug targets and therefore could 
have therapeutic applications in colorectal cancer. 
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Figure legends 
 
Figure 1. 
The overall relationship between the expression of CYP4A11 and survival in the whole 
patient cohort using different cut-off points: negative versus weak versus moderate versus 
strong (A, further details of median survival times of individual groups, p-values and hazard 
ratios are found in Table S4), strong versus negative/weak/moderate (B), positive expression 
versus negative expression (C) and negative and weak versus moderate and strong (D).  
 
Figure 2. 
The overall relationship between the differential expression of CYP4A11 and CYP4F11 and 
survival in the whole patient cohort (A), in MMR proficient tumours (B) and in MMR 
deficient tumours (C). Further details of median survival times of individual groups, p-values 
and hazard ratios are found in Table S6 
 
Figure 3. 
The relationship between the expression of CYP4A11 and survival in MMR proficient 
tumours using different cut-off points: negative versus weak versus moderate versus strong 
(A, further details of median survival times of individual groups, p-values and hazard ratios 
are found in Table S4), strong versus negative/weak/moderate (B) and positive expression 
versus negative expression (C). 
Table 1.  Clinico-pathological characteristics of all patients, their tumours and the 
relationship of each variable with overall survival. 
Characteristic Number Percentage Relationship with survival 
Sex 
Male 340 52.3 χ2= 0.027, p=0.870 
Female 310 47.7  
Age 
<70 305 46.9 χ2=29.213, p<0.001 
≥70 345 53.1  
Screen detected 
Yes 52 8 χ2=16.381, p<0.001 
No 598 92  
Tumour site 
Proximal colon 261 40.2 Proximal v distal, χ2= 8.418, p=0.004 
Distal colon 245 37.7 Distal v rectal, χ2= 0.906, p=0.341 
Rectum 144 22.2 Colon v rectum, χ2=0.098, p=0.754 
Tumour differentiation 
Well/moderate 600 92.3 χ2=0.976, p=0.323 
Poor 50 7.7  
Extra-mural venous invasion 
Present 140 21.5 χ2=100.946, p<0.001 
Absent 510 78.5  
Microsatellite instability status 
Defective 96 15.2 χ2=2.848, p=0.091 
Intact 536 84.8  
pT stage 
T1 30 4.6 T1 v T2, χ2=0.382, p=0.536 
T2 114 17.5 T2 v T3, χ2=24.739, p<0.001 
T3 411 63.2 T3 v T4, χ2=30.159, p<0.001 
T4 95 14.6  
pN stage 
N0 364 56 N0 v N1, χ2=54.071, p<0.001 
N1 177 27.2 N1 v N2, χ2=17.636, p<0.001 
N2 109 16.8  
Dukes stage 
A 120 18.5 A v B, χ2=5.059, p=0.025 
B 244 37.5 B v C, χ2=65.510, p<0.001 
C 286 44  
Significant values are highlighted in bold. 
 
Table 2.  Comparison of the expression of CYP4’s in normal colonic mucosa, primary colorectal cancer and lymph node metastasis. 
 
 
 
 
 
 
 
 
 
Evaluation of normal colonic epithelium versus primary tumour samples for immunoreactivity (Mann-Whitney U test, ↑=increased in tumour, 
↓=decreased in tumour, =no change between tumour and normal) and evaluation of primary Dukes C colorectal tumour samples and their 
corresponding metastasis samples for immunoreactivity (Wilcoxon signed rank sum test, ↑=increased in lymph node metastasis, ↓=decreased in 
lymph node metastasis, -=no change between primary and metastatic tumour).  Significant values are highlighted in bold. 
 
 Immunoreactivity 
(p value, normal 
versus primary 
tumour) 
Change in 
expression in 
tumour 
Immunoreactivity (p 
value, primary 
tumour versus lymph 
node metastasis) 
Change in 
expression in 
lymph node 
Immunoreactivity (p 
value, paired primary 
Dukes C tumour versus 
lymph node metastasis) 
Change in 
expression in 
lymph node 
CYP4A11 p<0.001 ↑ p=0.007 ↓ p=0.002 ↓ 
CYP4F11 p<0.001 ↑ p<0.001 ↓ p<0.001 ↓ 
CYP4V2 p<0.001 ↑ p<0.001 ↓ p<0.001 ↓ 
CYP4Z1 p=0.303 - p=0.028 ↓ p=0.083 - 
Table 3.  The final multivariate model showing the significance of the differential expression of CYP4A11 and CYP4F11 in multivariate 
analysis for the whole patient cohort and MMR proficient tumours. 
 Whole patient cohort MMR proficient tumours 
 Wald value p-value Hazard ratio (95% CI) Wald value p-value Hazard ratio (95% CI) 
Age (< 70 v ≥ 70) 31.115 <0.001 1.982 (1.554-2.529) 25.568 <0.001 1.993 (1.526-2.604) 
EMVI (present v absent) 38.825 <0.001 2.278 (1.758-2.951) 29.637 <0.001 2.245 (1.678-3.004) 
Dukes stage (Av B v C) 53.435 <0.001 2.826 (0.762- 4.191) 35.144 <0.001 2.622 (0.785-3.961) 
Differential expression of CYP4A11 and 
CYP4F11 (CYP4A11>CYP4F11 v 
CYP4A11=CYP4F11 v CYP4A11<CYP4F11) 
5.515 0.019 1.186 (1.029-1.368) 3.983 0.046 1.173 (1.003-1.371) 
 Significant values are highlighted in bold.  Details of the intermediate steps and omnibus tests of model coefficients are shown in 
Supplementary Tables S12 and S13. 
CYP4A11 neg 
CYP4A11 weak 
CYP4A11 mod 
CYP4A11 strong 
HR=1.135, 95%CI=1.032-1.249, χ2=9.080, p=0.028  
Number at risk 
CYP4A11 neg        175       105        75        25        0        0 
CYP4A11 weak       129        79        28         7        0        0 
CYP4A11 mod        124        65        23         7        0        0 
CYP4A11 strong     197        97        35     11        0        0 
CYP4A11 neg 
CYP4A11 weak/mod/strong 
HR=1.346, 95%CI=1.032-1.756, χ2=4.881, p=0.027  
Number at risk 
CYP4A11 neg                175       105       51        15         2         0               
CYP4A11 weak/mod/strong    450       249       88        27         0         0     
  
CYP4A11 neg/weak 
CYP4A11 mod/strong 
HR=1.235, 95%CI=0.983-1.552, χ2=3.315, p=0.069  
Number at risk 
CYP4A11 neg/weak       304        191       80        23        2         0 
CYP4A11 mod/strong     321     163       59        19        0         0 
CYP4A11 neg/weak/mod 
CYP4A11 strong 
HR=1.379, 95%CI=1.089-1.746, χ2=7.234, p=0.007  
Number at risk 
CYP4A11 neg/weak/mod  428       257       103       31         2         0 
CYP4A11 strong        197        97        35       11         0         0  
A 
B 
C 
D 
HR=1.203, 95%CI=1.092-1.324, χ2=14.968, p=0.001  
CY4A11<CYP4F11 
CY4A11=CYP4F11 
CY4A11>CYP4F11 
Number at risk 
CYP4A11<CYP4F11     214        140       67         21        3         0   
CYP4A11=CYP4F11     185        107       42         12        0         0  
CYP4A11>CYP4F11     217        103       29          9        1         0   
HR=1.276, 95%CI=1.095-1.488, χ2=9.988, p=0.007  
CY4A11<CYP4F11 
CY4A11=CYP4F11 
CY4A11>CYP4F11 
Number at risk 
CYP4A11<CYP4F11     186        120       53        17        2          0 
CYP4A11=CYP4F11     148         94       35         9        0          0  
CYP4A11>CYP4F11     181         87       25         9        1          0  
HR=1.433, 95%CI=0.993-2.067, χ2=5.676, p=0.059  
CY4A11<CYP4F11 
CY4A11=CYP4F11 
CY4A11>CYP4F11 
Number at risk 
CYP4A11<CYP4F11      23         17        11         3        0         0 
CYP4A11=CYP4F11      33         11         6         2        0         0 
CYP4A11>CYP4F11      33         15         5         1        0         0   
B 
A 
C 
CYP4A11 neg 
CYP4A11 weak 
CYP4A11 strong 
CYP4A11 mod 
HR=1.156, 95%CI=1.040-1.286, χ2=11.221, p=0.011  
Number at risk  
CYP4A11 neg    144        89        39        12        1         0 
CYP4A11 weak   107        74        24         7        0         0 
CYP4A11 mod     99        55        20         5        0         0 
CYP4A11 strong 173       85        28         9        0         0       
CYP4A11 neg 
CYP4A11 weak/mod/strong 
HR=1.375, 95%CI=1.022-1.851, χ2=4.485, p=0.034  
Number at risk 
CYP4A11 neg             144       89        39        12         1         0    
CYP4A11 weak/mod/strong 379      216        74        23      0         0  
CYP4A11 neg/weak/mod 
CYP4A11 strong 
HR=1.491, 95%CI=1.152-1.929, χ2=9.404, p=0.002  
Number at risk 
CYP4A11 neg/weak/mod  350        220       84        26         1        0 
CYP4A11 strong   173         85       28         9         0        0     
A 
C 
B 
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Supplementary information 
 
Materials and methods S1 
 
Monoclonal antibodies 
 Multiple sequence alignments were performed using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). To avoid undesirable regions such as 
transmembrane regions and signal peptides, the secondary and tertiary structures of proteins 
were predicted using tools such as http://wlab.ethz.ch/protter/start/ 
and http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index.  The B cell epitope 
prediction software available at (http://tools.immuneepitope.org/bcell/) predicts polypeptide 
stretches of amino acids that are accessible, flexible, and hydrophilic.  Furthermore, BLAST 
against UniProtKB 'Complete database' (http://web.expasy.org/blast/) was performed to 
ensure that the selected peptides are unique to the targets of interest.  Finally, Vertebrate 
Antibodies Ltd utilised its own optimized computer algorithm to select the ideal peptides to 
ensure antigenicity. 
 
The histopathological processing of tissues specimens  
 All specimens were received fresh in the diagnostic histopathology laboratory.  The 
specimens were fixed in 10% neutral buffered formalin for at least 48 hours at room 
temperature after they were opened along the anti-mesenteric border proximal (distal to the 
tumour when appropriate) and washed in cold water.  Representative tissue blocks were 
embedded in wax and sections were then stained with haematoxylin and eosin for 
histopathological diagnosis.  The sections were also stained with elastic haematoxylin and 
eosin to permit further assessment of extramural venous invasion when required.  The mean 
lymph node yield for all tumours in this study was 14.29 lymph nodes per tumour and for 
node negative tumours the mean lymph node yield was 15.07. 
  
Construction of colorectal cancer tissue microarray  
 The tissue microarray was constructed using 50 normal colon mucosal samples which 
were acquired from at least 10 cm distant from the tumour, 650 primary and 285 metastatic 
colorectal cancer samples.  Tumours were from patients had undergone elective surgery for 
primary colorectal cancer in the following periods; 1994-1998 (n=99), 1999-2003 (n=198) 
and 2004-2009 (n=353).  The metastases were all from tumour involved lymph nodes of the 
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Dukes C cases.  All the cases were reviewed and areas of tissue to be sampled were first 
identified and marked on the appropriate haematoxylin and eosin stained slide by an expert 
consultant gastro-intestinal pathologist (GIM).  Two cores measuring 1mm in diameter were 
taken from these areas of the corresponding wax embedded block and placed in a recipient 
paraffin block.  
 
Immunohistochemistry procedure  
 The tissue microarray sections were dewaxed in xylene for a minimum of 10 minutes 
and rehydrated by immersion in decreasing ethanol concentrations.  Antigen retrieval was 
performed when required and it consisted of heating the sections by microwaving (800W) for 
20 minutes.  During the microwaving, the sections were fully immersed in citrate buffer (pH 
6.0).  The slides were incubated with undiluted primary antibody for 60 minutes at room 
temperature.  After being washed twice with buffer (Dako) the sections were blocked with 
peroxidase for 7 minutes which was followed by two buffer washes.  Thereafter peroxidase-
polymer labelled goat anti-mouse secondary antibody (Envision, Dako) was applied for 30 
minutes at room temperature and followed by further two washes with buffer.  Then the 
diaminobenzidine substrate was applied for 7 minutes to reveal sites of peroxidase activity.  
The sections were washed in water, immersed in copper sulphate for 2 minutes 
counterstained with haematoxylin for 10 seconds, and placed in Scott’s tap water substitute 
for 2 minutes.  Finally dehydrated in increasing ethanol concentrations, immersed in a xylene 
and mounted.  As a negative control antibody diluent was used to replace the primary 
monoclonal antibody.  Normal liver tissue known to express all the enzymes was used as a 
positive control. 
 
Data analysis and statistics    
 Biomarkers were first assessed separately using Kaplan-Meier (log rank test) and Cox 
regression univariate analysis to determine the best risk classifier among individual CYP4 
markers. Duke’s stage and extramural venous are the main prognostic parameters currently 
used in CRC to risk stratify patients to different subgroups and therefore new prognostic 
biomarkers need to be examined in relation to these parameters to determine if the 
relationship is specific to one subgroup.  The anatomical site of primary colorectal cancer is 
also an important factor which affects the initial assessment, treatment and prognosis.  
Furthermore, colon (proximal and distal) and rectum differ in terms of their embryological 
origin, anatomy and may have distinct molecular profiles.  
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Furthermore, Kaplan-Meier survival analysis (stratified by other CYP4) was used to 
examine the overall relationship of the expression of CYP4 enzymes with outcome.  The aim 
of this analysis was to determine the prognostic value of using a combination of CYP4 
markers.   
 Key measurements used to determine the best prognostic marker include; the ability 
to distinguish between low and high risk groups (Kaplan-Meier plot), variations between risk 
groups (mean or median survival), chi-square value, p-value and hazard ratio with 95% 
confidence intervals.   
 A multivariate Cox’s proportional hazard model “Forward Stepwise: Conditional LR” 
was used to determine the prognostic significance of CYP4 markers.  The model included 
only established prognostic parameters and biomarkers with the best risk classification.   
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Results S1 
 
Survival analysis in colon cancers 
 There was a significant association between the intensity of CYP4A11 
immunostaining and overall survival in colon cancers (HR=1.153, 95% CI=1.033-1.287, 
χ2=10.084, p=0.018) (Supplementary Figure S6).  When each level of the intensity groups of 
CYP4A11 expression was considered separately using pairwise comparisons and one 
reference group (negative expression), strong intensity of CYP4A11 immunostaining was 
associated with poorer outcome (HR=1.640, 95% CI=1.168-2.302, χ2=7.953, p=0.005) 
(Supplementary Table S15).  Comparing strong CYP4A11 expressing tumours with 
negative/weak/moderate CYP4A11 expressing tumours also showed a significant association 
with survival (HR=1.494, 95% CI=1.135-1.967, χ2=8.354, p=0.004).  Similarly, the 
immunoreactivity of CYP4A11 was significantly associated with survival when CYP4A11 
negative tumours were compared with CYP4A11 positive tumours (HR=1.354, 95% 
CI=1.005-1.824, χ2=4.045, p=0.044).  The expression of CYP4A11 was independently 
prognostic (p=0.017) when using only parameters available at time of biopsy (Supplementary 
Table S16C). 
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Table S1.  Peptide sequences used as immunogens to generate monoclonal antibodies. 
 
Enzyme Hybridoma clone Peptide sequence Amino acid location 
CYP4A11 M25-P2A10 KNGIHLRLR 499 – 507 
CYP4F11 F21 P6 F5 RVEPLGANSQ 514 – 524 
CYP4V2 M29P3B10 KREELGLEGQ 495 – 504 
CYP4Z1 N7P2G5*D8 KLAPDHSRPP 473 – 483 
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Table S2.  The relationship between the expression of each cytochrome P450 and individual pathological parameter. 
A. CYP4A11 
Pathological parameter Number (percent) of patients in each group Chi-square  p-value 
Bowel screening programme detected Yes=49 (7.8%)  No=576 (92.2%) 3.673 0.299 
Colon or rectum Colon=485 (77.6%)  Rectum=140 (22.4%) 13.487 0.004 
Tumour site 
Proximal colon=246 (39.4%)  
Distal colon=239 (38.2%)  
Rectum=140 (22.4%) 
15.703 0.015 
Tumour differentiation Well/moderate=577 (92.3%) Poor=48 (7.7%)  3.816 0.282 
EMVI Absent=489 (78.2%)  Present=136 (21.8%) 5.911 0.116 
MMR status Intact=523 (85.3%) Defective=90 (14.7%)  2.303 0.512 
Tumour stage 
T1=29 (4.6%)  
T2=112 (18%)  
T3=390 (62.4%)  
T4=94 (15%) 
15.585 0.076 
Nodal stage 
N0=348 (55.7%) 
N1=169 (27%)  
N2=108 (17.3%) 
9.852 0.131 
Dukes stage 
A=117 (18.7%)  
B=231 (37%)  
C=277 (44.3%) 
13.148 0.041 
Number (percent) of patients classified by the level of CYP4A11 expression; negative= 175 (28%), weak=129 (20.7%), moderate=124 (19.8%) 
and strong=197 (31.5%).  Significant values are highlighted in bold. 
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B. CYP4F11  
 
Pathological parameter Number (percent) of patients in each group Chi-square  p-value 
Bowel screening programme detected Yes=580 (92.1%) No=50 (7.9%)   0.486 0.922 
Colon or rectum Colon=490 (77.8%)  Rectum=140 (22.2%) 17.026 0.001 
Tumour site 
Proximal colon=254 (40.3%)  
Distal colon=236 (37.5%)  
Rectum=140 (22.2%) 
20.947 0.002 
Tumour differentiation Well/moderate=580 (92.1%) Poor=50 (7.9%)  8.552 0.036 
EMVI Absent=493 (78.3%)  Present=137 (21.7%) 7.563 0.056 
MMR status Intact=523 (84.9%) Defective=93 (15.1%)  13.441 0.004 
Tumour stage 
T1=30 (4.8%)  
T2=113 (17.9%)  
T3=392 (62.2%)  
T4=95 (15.1%) 
11.008 0.275 
Nodal stage 
N0=355 (56.3%)  
N1=168 (26.7%)  
N2=107 (17%) 
10.656 0.100 
Dukes stage 
A=119 (18.9%)  
B=236 (37.5%)  
C=275 (43.6%) 
10.517 0.104 
Number (percent) of patients classified by the level of CYP4F11 expression; negative=53 (8.4%), weak=247 (39.2%), moderate=236 (37.5%) 
and strong=94 (14.9%).  Significant values are highlighted in bold. 
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C. CYP4V2 
Pathological parameter Number (percent) of patients in each group Chi-square  p-value 
Bowel screening programme detected Yes=49 (7.8%)  No=576 (92.2%) 4.644   0.200 
Colon or rectum Colon=486 (77.8%)  Rectum=139 (22.2%) 0.975   0.807 
Tumour site 
Proximal colon=250 (40%)  
Distal colon=236 (37.8%)  
Rectum=139 (22.2%) 
11.965   0.063 
Tumour differentiation Well/moderate=575 (92%) Poor=50 (8%)  1.759   0.616 
EMVI Absent=490 (78.4%)  Present=135 (21.6%) 3.174   0.365 
MMR status Intact=519 (84.8%) Defective=93 (15.2%)  7.231   0.065 
Tumour stage 
T1=30 (4.8%)  
T2=113 (18.1%)  
T3=389 (62.2%)  
T4=93 (14.9%) 
17.837   0.037 
Nodal stage 
N0=353 (56.5%)  
N1=165 (26.4%)  
N2=107 (17.1%) 
2.205   0.900 
Dukes stage 
A=119 (19.1%) 
B=234 (37.4%)  
C=272 (43.5%) 
24.474 <0.001 
Number (percent) of patients classified by the level of CYP4V2 expression; negative=336 (59.5%), weak=219 (35%), moderate=28 (4.5%) and 
strong=6 (1%).  Significant values are highlighted in bold. 
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Table S3.  The relationship between the expression of each cytochrome P450 and survival using different cut-off points for the intensity of the 
immunostaining. 
Significant values are highlighted in bold.   
 
 
 
 
CYP4A11 
Negative=175 (28%)  
Weak=129 (20.7%)  
Moderate=124 (19.8%)  
Strong=197 (31.5%) 
Negative=175 (28%)  
Weak/moderate /strong=450 (71.2%) 
Negative/weak=304 (48.7%)  
Moderate/strong=321 (51.3%) 
Strong=197 (31.5%)  
Negative/weak/moderate=428 (68.5%) 
 
χ2=9.080, p=0.028 
 
 
χ2=4.881, p=0.027 
 
χ2=3.315, p=0.069 χ2=7.234, p=0.007 
CYP4F11 
 
Negative=53 (8.4%)  
Weak=247 (39.2%), 
Moderate=236 (37.5%)  
Strong=94 (14.9%) 
Negative=53 (8.4%)  
Weak/moderate/strong=577 (91.6%) 
Negative/weak=300 (47.6%) 
Moderate/strong=330 (52.4%) 
Strong=94 (14.9%)  
Negative/weak/moderate=536 (85.1%) 
 
χ2=3.411, p=0.333 
 
 
χ2=2.054, p=0.152 
 
 
χ2=1.376, p=0.241 
 
 
χ2=1.697, p=0.193 
 
CYP4V2 
 
Negative=372 (59.5%)  
Weak=219 (35%) 
Moderate=28 (4.5%)  
Strong=6 (1%) 
Negative=372 (59.5%) 
Weak/moderate/strong=253 (40.5%) 
Negative/weak=591 (94.5%) 
Moderate/strong=34 (5.5%) 
Strong=6 (1%)  
Negative/weak/moderate=619 (99%) 
 
χ2=2.339, p=0.505 
 
 
χ2=0.093, p=0.761 
 
 
χ2=1.656, p=0.198 
 
 
χ2=0.014, p=0.907 
 
CYP4Z1 - - - - 
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Table S4.  The association between the expression of CYP4A11 and survival in the whole patient cohort and in MMR proficient tumours. 
CYP4A11 
categories 
Number (percent) 
of patients in each 
group 
Mean and median survival in months Pairwise comparisons: negative expression as a 
reference group 
Mean (95% CI) Median (95% CI) Chi-square p-value  Hazard ratio (95% CI) 
Whole cohort 
Negative 175 (28%) 132 (117-147) 137 (undefined) - - - 
Weak 129 (20.7%) 104 (90-119) 95 (63-126) 1.892 0.169 1.277 (0.912-1.789) 
Moderate 124 (19.8%) 106 (93-119) 115 (79-151) 0.305 0.581 1.127 (0.790-1.608) 
Strong 197 (31.5%) 96 (83-109) 75 (58-91) 8.006 0.005 1.541 (1.144-2.077) 
MMR proficient tumours 
Negative 144 (27.5%) 134 (118-151) 137 (undefined) - - - 
Weak 107 (20.5%) 105 (90-121) 95 (67-122) 1.823 0.177 1.298 (0.893-1.887) 
Moderate 99 (18.9%) 111 (97-126) 125 (90-159) 0.014 0.905 1.045 (0.695-1.571) 
Strong 173 (33.1%) 96 (82-109) 74 (57-91) 8.626 0.003 1.644 (1.183-2.284) 
Significant values are highlighted in bold.  When the cumulative survival proportion of patients was more than half the group, the median 
survival and/or its 95% confidence interval were undefined by SPSS.
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Table S5.  The relationship between the expression of CYP4A11 and CYP4F11 and survival in the whole cohort. 
 
A. The relationship between the expression of CYP4A11 and survival in the whole patient cohort stratified by CYP4F11. 
 CYP4F11   CYP4A11  
Number (percent) of 
patients in each group 
Mean and median survival in months 
Chi-square  p-value Hazard ratio (95% CI) 
Mean (95% CI) Median (95% CI) 
Negative 
Negative 28 (55%) 86 957-115) 53 (9-97) 
5.668 0.017 1.385 (1.057-1.815) 
Positive 23 (45%) 84 (57-111) 93 (26-160) 
Positive 
Negative 147 (26%) 139 (123-155)  Undefined 
Positive 418 (74%) 107 (97-116) 89 (71-107) 
Significant values are highlighted in bold.  When the cumulative survival proportion of patients was more than half the group, the median 
survival and/or its 95% confidence interval were undefined by SPSS. 
 
 
 
B. The relationship between the expression of CYP4F11 and survival in the whole patient cohort stratified by CYP4A11. 
CYP4A11   CYP4F11  
Number (percent) of 
patients in each group 
Mean and median survival in months 
Chi-square  p-value Hazard ratio (95% CI) 
Mean (95% CI) Median (95% CI) 
Negative 
Negative 28 (16%)  86 (57-115) 53 (9-97) 
4.844 0.028 0.657 (0.450-0.959) 
Positive 147 (84%) 139 (123-155) Undefined 
Positive 
Negative 23 (5.2%) 84 (57-111)  93 (26-160) 
Positive 418 (84.8%) 107 (97-116)  89 (71-107) 
Significant values are highlighted in bold.  When the cumulative survival proportion of patients was more than half the group, the median 
survival and/or its 95% confidence interval were undefined by SPSS. 
 
12 
 
Table S6.  The relationship between the differential expression of CYP4A11 and CYP4F11 and survival in the whole patient cohort, in MMR 
proficient tumours and in MMR deficient tumours. 
 
Differential expression of 
CYPA11 and CYP4F11 
Number (percent) 
of patients in each 
group 
Mean and median survival in months Pairwise comparisons: CYP4F11>CYP4A11 as 
a reference group 
Mean (95% CI) Median (95% CI) Chi-square p-value Hazard ratio (95% CI) 
Whole cohort 
CYP4A11< CYP4F11 214 (34.8%) 137 (124-151) Undefined) - - - 
CYP4A11=CYP4F11 185 (30%) 102 (91-114) 95 (72-117) 5.425   0.020 1.432 (1.064-1.928) 
CYP4A11>CYP4F11 217 (35.2%) 94 (82-107) 75 (60-89) 14.405 <0.001 1.733 (1.306-2.300) 
MMR proficient tumours 
CYP4A11< CYP4F11 186 (36.1%) 137 (123-152) Undefined) - - - 
CYP4A11=CYP4F11 148 (28.7%) 106 (84-112) 107 (83-131) 2.070   0.150 1.275 (0.918-1.770) 
CYP4A11>CYP4F11 181 (35.2%) 97 (110-128) 75 (85-121) 9.261   0.002 1.629 (1.199-2.214) 
MMR deficient tumours 
CYP4A11< CYP4F11 23 (25.8%) 133 (101-166) 153 (102-204) - - - 
CYP4A11=CYP4F11 33 (37.1%) 82 (56-109) 41 (25-56) 4.782   0.029 2.507 (1.098-5.725) 
CYP4A11>CYP4F11 33 (37.1%) 76 (54-98) 75 (25-124) 4.973   0.026 2.390 (1.036-5.511) 
Significant values are highlighted in bold.  When the cumulative survival proportion of patients was more than half the group, the median 
survival and/or its 95% confidence interval were undefined by SPSS.      
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Table S7.  The relationship of the expression of each cytochrome P450 and survival using individual cut-off points for immunostaining intensity 
with groups stratified by proximal and distal colon cancers. 
Significant values are highlighted in bold.  Numbers (percent) of patients classified by the level of each CYP4 expression are given in Table S3. 
 
 
 
Number (percent) of 
patients in each 
group 
 
Negative versus weak 
versus moderate versus 
strong 
Negative versus weak, 
moderate and strong 
Negative and weak 
versus moderate and 
strong 
Strong versus 
negative, weak and 
moderate 
Chi-square p-value Chi-square p-value Chi-square p-value Chi-square p-value 
CYP4A11 
Proximal    246 (50.7%) 3.455 0.327 1.598 0.206 0.180 0.671 1.456 0.228 
Distal    239 (49.3%) 7.764 0.051 2.128 0.145 3.299 0.069 7.545 0.006 
CYP4F11 
Proximal  254 (51.8%) 1.983 0.576 1.752 0.186 0.826 0.363 0.090 0.764 
Distal  236 (48.2%) 1.241 0.743 0.119 0.730 0.093 0.761 1.137 0.286 
CYP4V2 
Proximal  250 (51.5%) 1.209 0.751 0.100 0.752 1.167 0.280 0.054 0.817 
Distal  236 (48.5%) 1.154 0.764 0.153 0.696 1.055 0.304 0.425 0.514 
CYP4Z1 
Proximal  - - - - - - - - - 
Distal  - - - - - - - - - 
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Table S8.  The relationship of the expression of each cytochrome P450 and survival using individual cut-off points for immunostaining intensity 
with groups stratified by individual Dukes stage. 
Significant values are highlighted in bold.  Numbers (percent) of patients classified by the level of each CYP4 expression are given in Table S3. 
 
Number (percent) 
of patients in each 
group 
Negative versus weak 
versus moderate versus 
strong 
Negative versus weak, 
moderate and strong 
Negative and weak 
versus moderate and 
strong 
Strong versus negative, 
weak and moderate 
Chi-square p-value Chi-square p-value Chi-square p-value Chi-square p-value 
CYP4A11 
Dukes A  117 (18.7%) 4.358   0.225 3.884 0.049 3.239 0.072 1.179 0.278 
Dukes B  231 (37%) 2.369   0.499 0.574 0.448 0.011 0.918 1.152 0.283 
Dukes C  277 (44.3%) 1.448   0.694 0.001 0.977 0.220 0.639 1.175 0.278 
CYP4F11 
Dukes A  119 (18.9%) 0.591   0.899 0.132 0.717 0.077 0.782 0.503 0.478 
Dukes B  236 (37.5%) 1.434   0.698 0.463 0.496 0.132 0.717 0.580 0.446 
Dukes C 275 (43.6%) 2.478   0.479 0.956 0.328 1.796 0.180 1.361 0.243 
CYP4V2 
Dukes A  119 (19.1%) 17.752 <0.001 6.895 0.009 4.966 0.026 0.113 0.737 
Dukes B  234 (37.4%) 0.772   0.856 0.511 0.475 0.406 0.524 0.066 0.797 
Dukes C  272 (43.5%) 2.257   0.521 0.536 0.464 1.495 0.221 0.000 0.992 
CYP4Z1 
Dukes A  - - - - - - - - - 
Dukes B  - - - - - - - - - 
Dukes C  - - - - - - - - - 
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Table S9.  The relationship of the expression of each cytochrome P450 and survival using individual cut-off points for immunostaining intensity 
 with groups stratified by EMVI status. 
Significant values are highlighted in bold.  Numbers (percent) of patients classified by the level of each CYP4 expression are given in Table S3. 
 
 
Number (percent) 
of patients in each 
group 
Negative versus weak 
versus moderate versus 
strong 
Negative versus weak, 
moderate and strong 
Negative and weak 
versus moderate and 
strong 
Strong versus negative, 
weak and moderate 
Chi-square p-value Chi-square p-value Chi-square p-value Chi-square p-value 
CYP4A11  
Present 136 (21.8%) 2.474 0.480 0.113 0.737 0.006 0.937 1.207 0.272 
Absent 489 (78.2%) 3.983 0.263 1.863 0.175 2.572 0.109 3.609 0.057 
CYP4F11  
Present 137 (21.7%) 1.983 0.576 1.752 0.186 0.826 0.363 0.090 0.764 
Absent 493 (78.3%) 1.241 0.743 0.119 0.730 0.093 0.761 1.137 0.286 
CYP4V2  
Present 135 (21.6%) 4.226 0.238 0.071 0.790 1.239 0.266 0.081 0.776 
Absent 490 (78.4%) 3.609 0.307 1.533 0.216 1.182 0.277 0.050 0.823 
CYP4Z1 
Present - - - - - - - - - 
Absent - - - - - - - - - 
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Table S10.  The relationship between the expression of each cytochrome P450 and survival using individual cut-off points for immunostaining 
intensity with groups stratified by tumour site (colon versus rectum). 
 
Significant values are highlighted in bold.  Numbers (percent) of patients classified by the level of each CYP4 expression are given in Table S3. 
 
Number (percent) 
of patients in each 
group 
Negative versus weak 
versus moderate versus 
strong 
Negative versus weak, 
moderate and strong 
Negative and weak 
versus moderate and 
strong 
Strong versus 
negative, weak and 
moderate 
Chi-square p-value Chi-square p-value Chi-square p-value Chi-square p-value 
CYP4A11   
Colon 485 (77.6%) 10.084 0.018 4.045 0.044 2.689 0.101 8.354 0.004 
Rectum 140 (22.4%) 1.093 0.779 0.918 0.338 0.863 0.353 0.204 0.651 
CYP4F11   
Colon 490 (77.8%) 2.677 0.444 2.083 0.149 0.693 0.405 0.917 0.338 
Rectum 140 (22.2%) 1.061 0.787 0.001 0.978 0.631 0.427 0.756 0.384 
CYP4V2   
Colon 486 (77.6%) 0.913 0.822 0.081 0.776 0.855 0.355 0.018 0.895 
Rectum 140 (22.4%) 3.507 0.320 1.292 0.256 0.850 0.356 0.030 0.862 
CYP4Z1 
Colon - - - - - - - - - 
Rectum - - - - - - - - - 
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Table S11.  The relationship between the expression of each cytochrome P450 and survival using different cut-off points for immunostaining 
intensity with groups stratified by MMR protein status. 
Significant values are highlighted in bold.  Numbers (percent) of patients classified by the level of each CYP expression are given in Table S3
 
Number (percent) 
of patients in each 
group 
Negative versus weak 
versus moderate versus 
strong 
Negative versus weak, 
moderate and strong 
Negative and weak 
versus moderate and 
strong 
Strong versus negative, 
weak and moderate 
Chi-square p-value Chi-square p-value Chi-square p-value Chi-square p-value 
CYP4A11   
Defective 90 (14.7%) 0.512 0.916 0.397 0.529 0.054 0.817 0.000 0.948 
Proficient 523 (85.3%) 11.221 0.011 4.485 0.034 3.085 0.079 9.404 0.002 
CYP4F11   
Defective 93 (15.1%) 5.232 0.156 4.682 0.030 1.463 0.226 0.005 0.944 
Proficient 523 (84.9%) 1.493 0.684 0.051 0.822 0.168 0.682 1.475 0.225 
CYP4V2   
Defective 93 (15.2%) 0.711 0.871 0.103 0.749 0.160 0.689 0.410 0.522 
Proficient 519 (84.8%) 2.261 0.520 0.000 0.997 1.539 0.215 0.041 0.839 
CYP4Z1 
Defective - - - - - - - - - 
Proficient - - - - - - - - - 
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Table S12.  Details of the intermediate calculations and omnibus tests of model coefficients leading to the final multivariate model in the whole 
patient cohort (Cox regression, method: “Forward Stepwise: Conditional LR”). 
 
Step 
-2 Log 
Likelihood 
Overall (score) Change from previous step Change from previous block 
Chi-square p-value Chi-square p-value Chi-square p-value 
1a 3359.217 105.103 <0.001 99.401 <0.001 99.401 <0.001 
2b 3326.576 154.375 <0.001 32.642 <0.001 132.043 <0.001 
3c 3291.934 187.809 <0.001 34.642 <0.001 166.684 <0.001 
4d 3286.356 194.243 <0.001 5.578   0.018 172.262 <0.001 
a. Variable entered at step number 1: Dukes stage (A v B v C). 
b. Variable entered at step number 2: EMVI (present v absent). 
c. Variable entered at step number 3: age at Surgery (< 70 v ≥ 70). 
d. Variable entered at step number 4: differential expression of CY4A11 and CYP4F11 (CYP4A11>CYP4F11 v CYP4A11=CYP4F11 v 
CYP4A11<CYP4F11). 
The summary of the final multivariate model is shown in Table 3. 
Significant values are highlighted in bold.   
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Table S13.  The intermediate steps and omnibus tests of model coefficients leading to the final multivariate prognostic model in mismatch repair 
proficient tumours (Cox regression, method: “Forward Stepwise: Conditional LR”). 
 
Step 
-2 Log 
Likelihood 
Overall (score) Change from previous step Change from previous block 
Chi-square p-value Chi-square p-value Chi-square P-value 
1a 2672.051 79.187 <0.001 60.993 <0.001 60.993 <0.001 
2b 2638.138 113.667 <0.001 33.913 <0.001 94.906 <0.001 
3c 2609.881 140.816 <0.001 28.258 <0.001 123.164 <0.001 
4d 2605.872 145.222 <0.001 4.008   0.045 127.172 <0.001 
a. Variable entered at step number 1: Dukes stage (A v B v C). 
b. Variable entered at step number 2: EMVI (present v absent). 
c. Variable entered at step number 3: age at Surgery (< 70 v ≥ 70). 
d. Variable entered at step number 4: differential expression of CY4A11 and CYP4F11 (CYP4A11>CYP4F11 v CYP4A11=CYP4F11 v 
CYP4A11<CYP4F11). 
The summary of the final multivariate model is shown in Table 3. 
Significant values are highlighted in bold.   
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Table S14.  The significance of the differential expression of CYP4A11 and CYP4F11 in multivariate analysis for the whole patient cohort and 
MMR proficient tumours including only parameters that would be available at biopsy. 
 Significant values are highlighted in bold.               
 
 
 
 
 
 
 
 Whole patient cohort Mismatch repair proficient tumours 
Variable Wald value p-value Hazard ratio (95% CI) Wald value p-value Hazard ratio (95% CI) 
Age (< 70 v ≥ 70) 25.585 <0.001 1.881 (1.472-2.403) 22.787 <0.001 1.926 (1.472-2.521) 
Gender (male v Female) 0.364   0.546 0.931 (0.738-1.174) 0.234   0.629 0.939 (0.726-1.213) 
Tumour site (colon v rectum) 0.114   0.735 0.954 (0.726-1.253) 0.262   0.609 0.926 (0.692-1.241) 
Tumour differentiation (well/moderate v poor) 0.017   0.895 1.029 (0.674-1.572) 2.023   0.155 0.653 (0.362-1.175) 
Differential expression of CYP4A11 and 
CYP4F11 (CYP4A11>CYP4F11 v 
CYP4A11=CYP4F11 v CYP4A11<CYP4F11) 
12.039   0.001 1.281 (1.114-1.474) 7.454   0.006 1.240 (1.063-1.448) 
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Table S15.The association between the expression of CYP4A11 and survival in colon cancer. 
CYP4A11 
categories 
Number (percent) 
of patients  
Mean and median survival in months Pairwise comparisons: negative expression as a 
reference group 
Mean (95% CI) Median (95% CI) Chi-square p-value Hazard ratio  (95% CI) 
Negative 146 (30.1%) 128 (113-144) 137 (undefined) - - - 
Weak 109 (22.5%) 103 (87-119) 95 (65-125) 1.710 0.191 1.285 (0.886-1.863) 
Moderate 89 (18.3%) 108 (92-125) 125 (82-167) 0.015 0.904 1.038 (0.683-1.578) 
Strong 141 (29.1%) 95 (79-110) 69 (52-85) 7.953 0.005 1.640 (1.168-2.302) 
Significant values are highlighted in bold.  When the cumulative survival proportion of patients was more than half the group, the median 
survival and/or its 95% confidence interval were undefined by SPSS. 
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Table S16.  Multi-variate analysis of CYP4A11 using only parameters that would be 
available at biopsy in the whole patient cohort, in MMR proficient tumours and in colon 
cancers. 
A. whole patient cohort 
Variable Wald value p-value Hazard ratio (95% CI) 
Age at Surgery (< 70 v ≥ 70) 23.422 <0.001 1.830 (1.433-2.337) 
Gender (male v female) 0.042 0.837 0.976 (0.773-1.232) 
Tumour site (Colon vs rectum) 0.066 0.798 0.965 (0.732-1.271) 
Tumour differentiation (Well/moderate v 
poor) 
0.225 0.635 0.896 (0.571-1.408) 
MSI status (proficient v deficient) 1.320 0.251 1.202 (0.878-1.647) 
CYP4A11 (strong v negative/weak/moderate) 6.306 0.012 1.361 (1.070-1.730) 
Significant values are highlighted in bold. 
 
B. MMR proficient tumours 
Variable Wald value p-value Hazard ratio (95% CI) 
Age at Surgery (< 70 v ≥ 70) 22.711 <0.001 1.909 (1.463-2.490) 
Gender (male v female) 0.072 0.789 0.966 (0.749-1.245) 
Tumour site (Colon v rectum) 0.147 0.701 0.945 (0.707-1.263) 
Tumour differentiation (Well/moderate v 
poor) 
2.120 0.145 0.646 (0.359-1.163) 
CYP4A11 (strong v negative/weak/moderate) 7.168 0.007 1.427 (1.100-1.852) 
Significant values are highlighted in bold. 
 
C. Colon cancer cases 
Variable Wald value p-value Hazard ratio (95% CI) 
Age at Surgery (< 70 v ≥ 70) 18.479 <0.001 1.881 (1.410-2.509) 
Gender (male v female) 0.066 0.797 0.966 (0.741-1.259) 
Tumour differentiation (Well/moderate v 
poor) 
0.417 0.518 0.851 (0.522-1.388) 
MSI status (proficient v deficient) 2.131 0.144 1.286 (0.917-1.802) 
CYP4A11 (strong v negative/weak/moderate) 5.668 0.017 1.403 (1.062-1.853) 
  Significant values are highlighted in bold.
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Figure S1 
Immunoblots of (59.3 kDa), CYP4V2 (60.7 kDa) and CYP4Z1 (59 kDa) monoclonal 
antibodies.  A. The left hand lane (-) of each panel contains empty vector cell lysate while the 
right hand lane (+) of each panel contains lysate prepared from cells overexpressing the 
relevant protein.  Five micrograms of each lysate was loaded per lane. 
 
 
 
 
 
 
 
 
 
 
 
 
Immunoblots of CYP4A11 (59.3 kDa), CYP4V2 (60.7 kDa) and CYP4Z1 (59 kDa) 
monoclonal antibodies.  B. microsomal fractions prepared from human liver tissues were 
used.  Thirty micrograms of microsomes was loaded per lane.
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Figure S2. 
Photomicrographs of CYP4A11, CYP4F11, CYP4V2 and CYP4Z1 in normal colonic 
mucosa, primary colorectal cancer and metastatic colorectal cancer. 
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Figure S3. 
The frequency distribution of the intensity of expression of CYP4A11, CYP4F11, CYP4V2 and CYP4Z1 in normal colonic mucosa, primary 
colorectal cancer and lymph node metastasis. 
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Figure S4.  
The relationship between the expression of CYP4F11 and survival in MMR defective tumours. 
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Figure S5. 
The prognostic impact of the differential expression of CYP4A11 and CYP4F11 in colorectal 
cancer.  A. The metabolism of arachidonic acid by CYP4A11 is the dominant pathway in 
tumours with CYP4A11 > CYP4F11 expression ratio.  These tumours will have worse 
prognosis since the metabolism of 20-HETE promotes the production of VEGF and MMP9.  
B. The metabolism of omega-3 fatty acids is the dominant pathway in tumours with the 
CYP4A11 < CYP4F11 expression ratio.  These tumours will have better prognosis since the 
production of VEGF and MMPs is inhibited by the metabolism of omega-3 fatty acids. 
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Figure S6. 
The relationship between the expression of CYP4A11 and survival in colon cancers using 
different cut-off points: negative versus weak versus moderate versus strong (A), strong 
versus negative/weak/moderate (B) and positive expression versus negative expression (C). 
 
